Union Budget 2026 sends a clear signal: India’s biologics and biosimilars future will be science-led, data-driven, and globally benchmarked.
With biopharma positioned as a strategic frontier sector and focused investments across manufacturing scale-up, regulatory modernization, NIPER expansion, and clinical trial infrastructure, the intent is clear. India is preparing to compete not just on cost, but on quality, evidence, and speed. For biologics and biosimilars, this is especially critical.
Success in this decade will depend on:
• Model-informed drug development (MIDD) and regulatory science.
• In silico evidence to de-risk comparability, immunogenicity, and clinical programs.
• Smarter, adaptive clinical trial design using virtual patients.
• Faster, more confident regulatory decision-making aligned with global standards.
• In-silico design of differentiated, non-patent-infringing formulations and delivery strategies while preserving biosimilarity.
At InSilicoMinds, we see the Budget as a strong validation of what the ecosystem now needs: AI-enabled Modeling & Simulation embedded across the biologics and biosimilars lifecycle, from early development through post-approval, enabling responsible innovation without trial-and-error or IP risk.
This is not theoretical. Through population pharmacokinetics (PopPK) modeling and model-informed regulatory support, InSilicoMinds helped CuraTeQ Biologics strengthen the totality-of-evidence for its trastuzumab biosimilar (BP02), contributing to a positive EMA-CHMP opinion and market authorization for DAZUBLYS. It is a clear example of how in-silico science is enabling Indian companies to compete and win on the global biologics stage.
The opportunity ahead is not incremental. It is a structural shift in how biologics are developed, evaluated, and approved. The next phase of India’s biopharma leadership will be built on in silico science, regulatory trust, and execution at scale.
